The pharmacological treatment of lung cancer has been dominated by the platinum analogs for over a decade and with no immediate replacements in sight, they are expected to play a core role in ling cancer management for the foreseeable future. However, this is not to say that the lung cancer market will stagnate over the next seven years. With the emergence of innovative, lower toxicity agents, treatment outcomes for patients with lung cancer look set to improve dramatically. With new treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer provides a detailed examination of the current lung cancer pipeline activities in 7 major pharmaceutical markets, together with in-depth analysis of the most promising classes and drugs in development to 2007 enabling you to competitively position your products, strengthen your marketing strategy and market penetration, expose potential threats to your business and target R&D resources more effectively.
